ClinicalTrials.gov record NCT07845188
Nutritional Status of Gaucher Disease Patients
Evaluation of the Nutritional Status of Gaucher's Disease Patients
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This cross-sectional observational study will assess the nutritional status of patients with confirmed Gaucher disease who attend follow-up at Assiut University Children's Hospital. Study measurements include a dietary history, anthropometric measurements (weight, height, BMI, mid‑arm circumference), and body composition by bioelectrical impedance analysis (BIA). Measurements are taken during a routine follow-up visit at the hospital.
What it is studying. The study is testing how common underweight and stunting are and describing body composition and anthropometric measures in patients with Gaucher disease.
What the researchers hope to learn. To estimate the prevalence of underweight and stunting in Gaucher disease patients and to describe average BMI, mid‑arm circumference, fat mass percentage, and lean body mass in this group.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
This cross-sectional study aims to evaluate the nutritional status of patients with Gaucher disease attending Assiut University Children's Hospital using anthropometric measurements and body composition analysis.
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Confirmed diagnosis of Gaucher disease (type 1, 2, or 3)
- Undergoing a follow-up visit at Assiut University Children's Hospital
- Written informed consent from caregivers
Exclusion criteria
- Other autosomal recessive lysosomal storage diseases
- Not undergoing a follow-up visit at Assiut University Children's Hospital
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Detailed description from the registry
Gaucher disease is a lysosomal storage disorder that may affect growth and nutritional status, particularly in children. This observational study will include patients with confirmed Gaucher disease (types 1, 2, and 3) who attend follow-up visits at Assiut University Children's Hospital. Nutritional status will be assessed by detailed dietary history, anthropometric measurements (weight, height, BMI, mid-arm circumference), and body composition analysis using bioelectrical impedance analysis (BIA).
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Caregivers will be asked to give written informed consent. During a study visit (conducted at a follow-up appointment) participants will be asked about their diet and have anthropometric measurements taken—weight, height, body mass index (BMI), and mid-arm circumference—and will undergo body composition analysis using bioelectrical impedance analysis (BIA). These baseline measurements will be used to assess underweight, stunting, BMI, arm circumference, fat mass percentage, and lean body mass. The registry record does not state any other procedures, such as blood tests or imaging, beyond those listed.
How the study is structured. This is an observational, cross‑sectional study of a single group of Gaucher disease patients. There is no treatment assignment or randomization. Each participant has a dietary history taken and undergoes anthropometric measurements (weight, height, BMI, mid‑arm circumference) and body composition analysis using bioelectrical impedance analysis (BIA). All data are collected at one point in time.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The registry says recruitment has not started. When is it expected to open, and can I register interest now?
- No sites are listed on the registry yet. Where will the study take place?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on Gaucher disease
Important dates
- Study start
- Sep 26, 2026 (estimated)
- Primary completion
- Sep 26, 2027 (estimated)
- Study completion
- Feb 25, 2028 (estimated)
- Target enrollment
- 84 participants (estimated)
- Last updated on registry
- Sep 28, 2026
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Assiut University
- Principal investigator
- Salma Hassanein Salem Ahmed, Resident Physician, Department of Pediatrics
Assiut University
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Salma H Salem, Resident 📞 +20 10 14620228 ✉ Salma.17308823@med.aun.edu.eg
Participating sites
Study locations have not been posted on ClinicalTrials.gov yet. This study is not yet recruiting, so sites may be added when recruitment begins. The central study contact above may be able to tell you about planned sites.
Terms used on this page · explanations by MedicalUpdates.ai
- follow-up
- The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
- Written informed consent
- The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials